2:
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR.
Blood. 2003 Jul 1;102(1):311-9. Epub 2003 Mar 20.
PMID: 12649140 [PubMed - indexed for MEDLINE]
Related Articles
3:
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T.
Blood. 2002 Sep 15;100(6):2195-202.
PMID: 12200385 [PubMed - indexed for MEDLINE]
Related Articles
11:
SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.
Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, Roodman GD, Lentzsch S.
Blood. 2007 Mar 1;109(5):2130-8. Epub 2006 Nov 9.
PMID: 17095620 [PubMed - indexed for MEDLINE]
Related Articles
20:
Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S.
Cancer Res. 2005 Mar 1;65(5):1700-9.
PMID: 15753365 [PubMed - indexed for MEDLINE]
Related Articles